Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07748299 | NuvOx Expanded Access | available | — | — | NuvOx LLCINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT06404034 | Expanded Access to Gallium Maltolate (GaM) | available | — | — | Imaging Biometrics, LLCINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04566393 |
| Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies |
| available |
| — |
| — |
| xCuresINDUSTRY |
| 1 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06676891 | Expanded Access Program for GBM Subjects | available | — | — | Rznomics, Inc.OTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02146066 | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221(DCVax-L EAP) | available | — | — | Northwest BiotherapeuticsINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 5, 2026source: clinicaltrials